Cue Biopharma
Clinical trials sponsored by Cue Biopharma, explained in plain language.
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called CUE-102 in 42 adults with advanced colorectal, gastric, pancreatic, or ovarian cancers that had stopped responding to standard treatments. Participants had a specific genetic marker (HLA-A*0201) and their tumors produced a protein c…
Phase: PHASE1 • Sponsor: Cue Biopharma • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
New hope for HPV-linked head and neck cancer: early trial tests targeted therapy
Disease control CompletedThis early-phase study tested a new drug called CUE-101, alone or with pembrolizumab, in 80 adults with HPV16-positive head and neck cancer that had spread or returned. The main goals were to check safety and find the right dose. Researchers also looked at how well the drug shran…
Phase: PHASE1 • Sponsor: Cue Biopharma • Aim: Disease control
Last updated May 22, 2026 13:50 UTC